Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 08:00 ET | Source: Microbot Medical Inc.

Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise...
October 01, 2025 09:00 ET | Source: Microbot Medical Inc.

Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio

Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum...
September 23, 2025 08:30 ET | Source: Microbot Medical Inc.

Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System

HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief...
September 16, 2025 15:37 ET | Source: Microbot Medical Inc.

Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

HINGHAM, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the first closing of its previously announced exercise of...
September 15, 2025 08:00 ET | Source: Microbot Medical Inc.

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds

BRAINTREE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the entry into definitive agreements for the exercise of...
September 09, 2025 08:28 ET | Source: Microbot Medical Inc.

REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference

HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, today announced that Harel...
September 08, 2025 08:28 ET | Source: Microbot Medical Inc.

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System.
August 20, 2025 08:30 ET | Source: Microbot Medical Inc.

Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications

With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial...
August 05, 2025 08:30 ET | Source: Microbot Medical Inc.

Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a...
July 22, 2025 08:30 ET | Source: Microbot Medical Inc.

Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

Microbot Medical has appointed seasoned medical device executive and two-time Olympian Christina Bailey as Vice President of Sales.